Company Profile
Atara Biotherapeutics, Inc. Stock Price, News & Catalysts
- Ticker:
- ATRA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
8.36 USD (+3.34%)
Close
Last updated: August 17, 2026
89.2M USD
Market cap
Why the stock is moving
As of Aug 17, 2026, ATRA closed up 3.34% at $8.36. No new same-company headline was identified in the current news window.
Company overview
Allogeneic EBV T-Cell Platform
Atara Biotherapeutics develops off-the-shelf T-cell therapies generated from healthy donors and directed against Epstein-Barr virus antigens. Its platform does not require T-cell-receptor or HLA gene editing.
Tabelecleucel
Tabelecleucel, also known as tab-cel or EBVALLO, is an allogeneic EBV-specific T-cell therapy for Epstein-Barr virus-positive post-transplant lymphoproliferative disease. The U.S. application is supported by the pivotal single-arm ALLELE study.
Partnered Regulatory Model
Pierre Fabre Pharmaceuticals controls the U.S. regulatory and commercial program. Atara supports the BLA resubmission and retains eligibility for an approval milestone, commercial milestones, and tiered royalties.
Future catalysts
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Atara Biotherapeutics, Inc. (ATRA)?
Atara Biotherapeutics, Inc. (ATRA) most recently closed at 8.36 USD, a +3.34% move versus the previous session.
What is the market cap of Atara Biotherapeutics, Inc. (ATRA)?
Atara Biotherapeutics, Inc. currently has a market capitalization of 89.2M USD on BioPharmSignal.
What does Atara Biotherapeutics, Inc. do?
Allogeneic EBV T-Cell Platform Atara Biotherapeutics develops off-the-shelf T-cell therapies generated from healthy donors and directed against Epstein-Barr virus antigens. Its platform does not require T-cell-receptor or HLA gene editing. Tabelecleucel Tabelecleucel, also known as tab-cel or EBVALLO, is an allogeneic EBV-specific T-cell therapy for...
On which exchange is ATRA stock listed?
Atara Biotherapeutics, Inc. (ATRA) is associated with NASDAQ, United States, Biopharma.
What is Allogeneic?
Allogeneic EBV T-Cell Platform Atara Biotherapeutics develops off-the-shelf T-cell therapies generated from healthy donors and directed against Epstein-Barr virus antigens.
Which conditions is Atara Biotherapeutics, Inc. targeting with Allogeneic?
Allogeneic EBV T-Cell Platform Atara Biotherapeutics develops off-the-shelf T-cell therapies generated from healthy donors and directed against Epstein-Barr virus antigens. Its platform does not require T-cell-receptor or HLA gene editing. Tabelecleucel Tabelecleucel, also known as tab-cel or EBVALLO, is an allogeneic EBV-specific T-cell therapy for...
What is T-Cell?
Allogeneic EBV T-Cell Platform Atara Biotherapeutics develops off-the-shelf T-cell therapies generated from healthy donors and directed against Epstein-Barr virus antigens.
What is Platform?
Allogeneic EBV T-Cell Platform Atara Biotherapeutics develops off-the-shelf T-cell therapies generated from healthy donors and directed against Epstein-Barr virus antigens.